Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis

References

• Markham A. Brolucizumab: first approval. Drugs. 2019;79(18):1997–2000. doi:10.1007/s40265-019-01231-9
   PubMed Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi:10.1016/j.ophtha.2019.04.017
   PubMed Web of Science ®Google Scholar
• Beovu update for ASRS members. American society of retina specialists; 2020. Available from: https://www.asrs.org/clinical/clinical-updates/960/Beovu-Update-for-ASRS-Members. Accessed August 31, 2023.
   Google Scholar
• Witkin AJ, Hahn P, Murray TG. Occlusive retinal vasculitis following intravitreal brolucizumab: an ASRS research and safety in therapeutics (ReST) committee report. Retina Times; 2020. Available from: https://www.asrs.org/publications/retina-times/details/2929/oclusive-retinal-vasculitis-following-intravitreal-brolucizumab-an-asrs-research-and-safety-in-thera. Accessed August 31, 2023.
   Google Scholar
• Witkin AJ, Hahn P, Murray TG. Occlusive retinal vasculitis following intravitreal brolucizumab: an ASRS research and safety in therapeutics (ReST) committee report. Retina Times. 2020;38(2):10–13.
   Google Scholar
• Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345–1359. doi:10.1016/j.ophtha.2020.04.017
   PubMed Web of Science ®Google Scholar
• Haug SJ, Hien DL, Uludag G, et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020;18:100680. doi:10.1016/j.ajoc.2020.100680
   PubMedGoogle Scholar
• Jain A, Chea S, Matsumiya W, et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020;18:100687. doi:10.1016/j.ajoc.2020.100687
   PubMedGoogle Scholar
• Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2020;S0161–6420(20):31075–31077. doi:10.1016/j.ophtha.2020.11.011
   Google Scholar
• Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina. 2010;30(7):1046–1050. doi:10.1097/IAE.0b013e3181d87e04
   PubMed Web of Science ®Google Scholar
• Moussa G, Bassilious K, Mathews N. A novel excel sheet conversion tool from Snellen fraction to LogMAR including ‘counting fingers’, ‘hand movement’, ‘light perception’ and ‘no light perception’ and focused review of literature of low visual acuity reference values. Acta Ophthalmol. 2020;99:e963–e965. doi:10.1111/aos.14659
   PubMed Web of Science ®Google Scholar
• Edwards A. Note on “correction for continuity” in testing the significance of the difference between correlated proportions. Psychometrika. 1948;13(3):185–187. doi:10.1007/BF02289261
   PubMedGoogle Scholar
• Hoffman JI. The incorrect use of chi-square analysis for paired data. Clin Exp Immunol. 1976;24(1):227–229.
   PubMed Web of Science ®Google Scholar
• McNEMAR Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika. 1947;12(2):153–157. doi:10.1007/BF02295996
   PubMed Web of Science ®Google Scholar
• Rasch D, Guiard V. The robustness of parametric statistical methods. Psychol Sci. 2004;46(2):175–208.
   Google Scholar
• Stepanov A, Studnicka J, Veith M, et al. Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: real-life Evidence in the Czech Republic. Eur J Ophthalmol. 2022:11206721221132619. doi:10.1177/11206721221132619
   Web of Science ®Google Scholar
• Abdin AD, Aljundi W, El Jawhari K, Suffo S, Weinstein I, Seitz B. First year real life experience with intravitreal brolucizumab for treatment of refractory neovascular age-related macular degeneration. Front Pharmacol. 2022;13:860784. doi:10.3389/fphar.2022.860784
   PubMed Web of Science ®Google Scholar
• Avaylon J, Lee S, Gallemore RP. Case series on initial responses to intravitreal brolucizumab in patients with recalcitrant chronic wet age-related macular degeneration. Int Med Case Rep J. 2020;13:145–152. doi:10.2147/IMCRJ.S252260
   PubMed Web of Science ®Google Scholar
• Awh CC, Davis EC, Thomas MK, Thomas AS. Short-term outcomes after interim treatment with brolucizumab: a retrospective case series of a single center experience. Retina. 2022;42(5):899–905. doi:10.1097/IAE.0000000000003418
   PubMed Web of Science ®Google Scholar
• Baumal CR, Bodaghi B, Singer M, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2021;5(6):519–527. doi:10.1016/j.oret.2020.09.020
   PubMedGoogle Scholar
• Chakraborty D, Maiti A, Sheth JU, et al. Brolucizumab in neovascular age-related macular degeneration - Indian real-world experience: the BRAILLE study. Clin Ophthalmol. 2021;15:3787–3795. doi:10.2147/OPTH.S328160
   PubMed Web of Science ®Google Scholar
• Chakraborty D, Maiti A, Sheth JU, et al. Brolucizumab in neovascular age-related macular degeneration - Indian real-world Experience: the BRAILLE study - fifty-two-week outcomes. Clin Ophthalmol. 2022;16:4303–4313. doi:10.2147/OPTH.S395577
   PubMed Web of Science ®Google Scholar
• Coney JM, Zubricky R, Sinha SB, et al. Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration. Int J Retina Vitreous. 2023;9(1):8. doi:10.1186/s40942-023-00445-0
   PubMedGoogle Scholar
• Corradetti G, Corvi F, Juhn A, Sadda SR. Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab. Am J Ophthalmol Case Rep. 2020;20:100981. doi:10.1016/j.ajoc.2020.100981
   PubMedGoogle Scholar
• Enríquez AB, Baumal CR, Crane AM, et al. Early experience with brolucizumab treatment of neovascular age-related macular degeneration. JAMA Ophthalmol. 2021;139(4):441–448. doi:10.1001/jamaophthalmol.2020.7085
   PubMed Web of Science ®Google Scholar
• Giunta M, Gauvin Meunier LP, Nixon D, Steeves J, Noble J. Early Canadian real-world experience with brolucizumab in anti-vascular endothelial growth factor-experienced patients with neovascular age-related macular degeneration: a retrospective chart review. Clin Ophthalmol. 2022;16:2885–2894. doi:10.2147/OPTH.S376199
   PubMed Web of Science ®Google Scholar
• Hoshino J, Matsumoto H, Mukai R, Nakamura K, Akiyama H. Intravitreal aflibercept versus brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization: comparison of short-term outcomes. Ophthalmologica. 2022;245(5):413–420. doi:10.1159/000526044
   PubMed Web of Science ®Google Scholar
• Khanani AM, Brown DM, Jaffe GJ, et al. MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with nAMD and persistent retinal fluid. Ophthalmology. 2022;S0161–6420(22):334. doi:10.1016/j.ophtha.2022.04.028
   Google Scholar
• Khanani AM, Zarbin MA, Barakat MR, et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS registry and komodo healthcare map. JAMA Ophthalmol. 2022;140(1):20–28. doi:10.1001/jamaophthalmol.2021.4585
   PubMed Web of Science ®Google Scholar
• Kim DJ, Jin KW, Han JM, et al. Short-term safety and efficacy of intravitreal brolucizumab injections for neovascular age-related macular degeneration: a multicenter retrospective real-world study. Ophthalmologica. 2023:1–11. doi:10.1159/000529410
   Web of Science ®Google Scholar
• Kitajima Y, Maruyama-Inoue M, Ikeda S, et al. Short-term outcomes of switching to brolucizumab in Japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol. 2022;66(6):511–517. doi:10.1007/s10384-022-00940-1
   PubMed Web of Science ®Google Scholar
• Kulikov AN, Gazizova IR, Maltsev DS, Malafeeva AY, Vasilyev AS, Zhalimova VR. Kratkosrochnye dannye effektivnosti i bezopasnosti primeneniya preparata «Brolutsizumab» pri lechenii neovaskulyarnoi vozrastnoi makulyarnoi degeneratsii na territorii Rossiiskoi Federatsii [Short-term Efficacy and Safety of Brolucizumab for Neovascular Age-related Macular Degeneration in the Russian Federation]. Vestn Oftalmol. 2022;138(3):55–62. Russian. doi:10.17116/oftalma202213803155
   PubMedGoogle Scholar
• Maruko I, Okada AA, Iida T, et al. Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol. 2021;259(9):2857–2859. doi:10.1007/s00417-021-05136-w
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Hoshino J, Nakamura K, Akiyama H. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization. Sci Rep. 2023;13(1):3249. doi:10.1038/s41598-023-30146-5
   PubMed Web of Science ®Google Scholar
• Mehta N, Fong RD, Wilson M, et al. Real-world experience using intravitreal brolucizumab alone or in combination with aflibercept in the management of neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:657–665. doi:10.2147/OPTH.S399590
   PubMed Web of Science ®Google Scholar
• Montesel A, Bucolo C, Sallo FB, Eandi CM. Short-term efficacy and safety outcomes of brolucizumab in the real-life clinical practice. Front Pharmacol. 2021;12:720345. doi:10.3389/fphar.2021.720345
   PubMed Web of Science ®Google Scholar
• Mukai R, Matsumoto H, Akiyama H. Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. PLoS One. 2021;16(12):e0259879. doi:10.1371/journal.pone.0259879
   PubMed Web of Science ®Google Scholar
• Murray JE, Gold AS, Latiff A, Murray TG. Brolucizumab: evaluation of compassionate use of a complex anti-VEGF therapy. Clin Ophthalmol. 2021;15:4731–4738. doi:10.2147/OPTH.S339393
   PubMed Web of Science ®Google Scholar
• Ota H, Takeuchi J, Nakano Y, et al. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration. Jpn J Ophthalmol. 2022;66(3):278–284. doi:10.1007/s10384-022-00908-1
   PubMed Web of Science ®Google Scholar
• Scupola A, Carlà MM, Boselli F, et al. Brolucizumab for wet age-related macular degeneration: one-year real-world experience from a tertiary center. Ophthalmologica. 2023;246:58–67. doi:10.1159/000529817
   PubMed Web of Science ®Google Scholar
• Sotani R, Matsumiya W, Kim KW, et al. Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023:23–36. doi:10.1007/s00417-023-06036-x
   PubMed Web of Science ®Google Scholar
• Ueda-Consolvo T, Tanigichi A, Numata A, et al. Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study. Graefes Arch Clin Exp Ophthalmol. 2023;261(2):345–352. doi:10.1007/s00417-022-05793-5
   PubMed Web of Science ®Google Scholar
• Van Cleemput L, Peeters F, Jacob J. Brolucizumab for neovascular age-related macular degeneration (BEL Study). Clin Ophthalmol. 2023;17:1077–1085. doi:10.2147/OPTH.S402090
   PubMed Web of Science ®Google Scholar
• Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. Brolucizumab: a newly developed Anti-VEGF molecule for the treatment of neovascular age-related macular degeneration. Ophthalmologica. 2021;244:93–101. doi:10.1159/000513048
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• DeCroos FC, Reed D, Adam MK, et al. Treat-and-extend therapy using aflibercept for neovascular age-related macular degeneration: a prospective clinical trial. Am J Ophthalmol. 2017;180:142–150. doi:10.1016/j.ajo.2017.06.002
   PubMed Web of Science ®Google Scholar
• Hahn P. ASRS 2023 Preferences and Trends Membership Survey. Chicago, IL: American Society of Retina Specialists; 2023.
   Google Scholar
• Khurana RN, Rahimy E, Joseph WA, et al. Extended (Every 12 Weeks or Longer) dosing interval with intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration: post hoc analysis of VIEW trials. Am J Ophthalmol. 2019;200:161–168. doi:10.1016/j.ajo.2019.01.005
   PubMed Web of Science ®Google Scholar
• Witkin AJ, Hahn P, Murray TG, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis. 2020;4(4):269–279. doi:10.1177/247412640930863
   PubMedGoogle Scholar